

REVIEW

Open Access

Engineering biodegradable and multifunctional peptide-based polymers for gene delivery

Julie Shi, Joan G Schellinger and Suzie H Pun*

Abstract

The complex nature of *in vivo* gene transfer establishes the need for multifunctional delivery vectors capable of meeting these challenges. An additional consideration for clinical translation of synthetic delivery formulations is reproducibility and scale-up of materials. In this review, we summarize our work over the last five years in developing a modular approach for synthesizing peptide-based polymers. In these materials, bioactive peptides that address various barriers to gene delivery are copolymerized with a hydrophilic backbone of *N*-(2-hydroxypropyl) methacrylamide (HPMA) using reversible-addition fragmentation chain-transfer (RAFT) polymerization. We demonstrate that this synthetic approach results in well-defined, narrowly-disperse polymers with controllable composition and molecular weight. To date, we have investigated the effectiveness of various bioactive peptides for DNA condensation, endosomal escape, cell targeting, and degradability on gene transfer, as well as the impact of multivalency and polymer architecture on peptide bioactivity.

Keywords: Nonviral gene delivery, Peptide-polymers, Endosomal escape, Degradability, *N*-(2-hydroxypropyl) methacrylamide (HPMA)

Gene therapy has the potential to improve therapeutic outcomes for currently untreatable diseases. Viruses are naturally efficient vectors for gene therapy, but have encountered obstacles in clinical translation due to issues such as vector toxicity and immunogenicity, potential gene integration into oncogenic regions, and high production costs. Thus, nonviral materials, *e.g.* cationic lipids and polymers, have been extensively engineered as gene delivery vectors and are attractive alternatives to viral vectors because they tend to have improved safety profiles and lower costs of production [1]. However, nonviral vectors have not been as successful in attaining high transgene expression efficiencies *in vivo*. In order to enhance the gene transfer efficiency of these materials, several groups have explored the use of bioactive peptides to address various extracellular and intracellular barriers to nonviral gene delivery, such as cellular uptake, endosomal escape, cargo unpackaging, and nuclear translocation [2-5]. These multicomponent synthetic materials have been engineered to overcome these barriers for various applications [6], including delivery to neurons [7] and hepatocytes [8].

Recent advances in living polymerization techniques, such as reversible-addition fragmentation chain transfer (RAFT), have allowed the development of well-defined polymers with controlled architectures and quantitative monomer incorporation [9-11]. Peptide-polymer conjugates containing multiple peptides can be synthesized by grafting peptides to preformed polymers or by polymerization of peptide monomers. The grafting technique has been extensively reviewed elsewhere [12-14]. The Klok group demonstrated the synthesis of peptide brush copolymers by RAFT polymerization of coiled coil peptide motifs in 2010 [15].

In this review, we summarize our work in the development of copolymers consisting of *N*-(2-hydroxypropyl) methacrylamide (HPMA) and multiple pendant oligopeptides for gene delivery (Figure 1). Cationic peptide moieties were explored and optimized for DNA condensation. To improve biodegradability, environmentally-responsive linkers were incorporated into the HPMA copolymers. In addition, both buffering and membrane-disruptive peptides were evaluated for enhancing endosomal escape of the polyplexes. Throughout our work, we have also noted effects of polymer architecture and multivalency on transfection efficiency. Finally, we conclude with some therapeutic

* Correspondence: spun@uw.edu
Department of Bioengineering and Molecular Engineering & Sciences Institute,
University of Washington, 3720 15th Ave NE, Seattle, WA 98195, USA




Figure 1 Schematic of peptide-functionalized HPMA copolymers. **(A)** Random-statistical copolymers of HPMA (red) and pendant bioactive peptides (green) with a linker (blue) between the hydrophilic backbone and the main peptide sequence. **(B)** Random-statistical copolymers of HPMA and multiple pendant peptides (cationic peptide in green; second bioactive peptide in purple). **(C)** Diblock copolymer of HPMA and multiple pendant peptides, where the cationic peptide is on one block, and a second bioactive peptide on a different block.

applications for this class of peptide-functionalized brush polymers that we have investigated.

Design of peptide-based polymers

Nucleic acid condensation using basic peptides

Cationic vectors can be used to form electrostatic complexes with anionic nucleic acid, termed “polyplexes”, to protect the nucleic acid from serum and intracellular proteases. Early studies demonstrated the use of poly-L-lysine as a transfection agent to deliver plasmid DNA to achieve exogenous protein expression [16]. Further work was conducted to optimize the oligolysine and polylysine residues for enhanced gene transfer, as well as introduce salt- and serum-stability into these carriers [17]. Since then, a number of cationic polymers have been developed for gene delivery applications [1,18]. In 1997, O’Brien-Simpson and coworkers reported a general method for the assembly of multi-peptide polymer constructs using acryloyl peptides by radical polymerization for vaccine development [19]. Thus, we hypothesized that this polymer architecture would enable a greater incorporation of peptide moieties and flexibility for multiple peptide incorporation for the development of gene delivery vectors.

As a starting point, HPMA was chosen to compose the hydrophilic backbone. HPMA has been widely used for the synthesis of polymer-drug conjugates due to its biocompatibility, as well as its synthetic versatility and flexibility since it has been used in a variety of polymerization techniques [20]. Therefore, we copolymerized short pendant oligolysine peptides with HPMA in a random-statistical brush polymer architecture using both free radical and RAFT polymerization approaches

(Figure 2) [21,22]. Polymers synthesized by RAFT polymerization exhibited polydispersities closer to 1, better control over final polymer composition, and reduced toxicities [23]. We next optimized the peptide length and molecular weight of these statistical polymers generated by RAFT polymerization, and found that a peptide length of 10 lysines, a composition of 5 mmol lysine per gram polymer, and a molecular weight of ~60 kDa was optimal for high transfection efficiencies (comparable to that of branched polyethylenimine, or bPEI) and limited cytotoxicity [23]. Surprisingly, a 50% longer oligolysine peptide (K_{15}) demonstrated poor transfection efficiencies despite similar lysine composition and molecular weight. Extensive studies on the mechanism of enhanced transfection of the optimized polymer ($p[HPMA-co-K_{10}]$) over the poorly-performing polymer ($p[HPMA-co-K_{15}]$) showed that polyplexes of larger aspect ratios (more rod-like) greatly reduced cellular uptake and subsequent transfection efficiency (Shi J, Choi JL, Chou B, Johnson RN, Schellinger JG, Pun SH: Effect of polyplex morphology on cellular uptake, intracellular trafficking, and transgene expression. Submitted). Previous studies have reported that polylysine length correlates to the aspect ratio of the lysine/DNA complexes, thus highlighting the importance of understanding the biophysical interaction of plasmid DNA with various cationic moieties. In order to reduce cytotoxicity, we explored the effect of reduced charge density by alternating lysine residues with glycine spacers ($p[HPMA-co-(GK)_5]$) since increased charge densities were found to correlate with greater cytotoxicities [24]. Interestingly, these polymers induced similar transfection efficiencies than its pentamer




Figure 2 Synthesis of statistical HPMA-oligolysine copolymers by RAFT polymerization. HPMA and methacrylamido-functionalized oligolysine peptides are copolymerized under aqueous RAFT conditions using ethyl cyanovaleic trithiocarbonate (ECT) as the chain transfer agent (CTA) [71] and VA-044 as the initiator. The 6-carbon aminohexanoic acid (Ahx) is used as a linker between the pendant oligolysine peptide and the hydrophilic backbone.

counterpart (p [HPMA-*co*-K₅]) but actually were more cytotoxic [25].

Arginine is another cationic amino acid residue that has been explored as a complexation agent. Arginine has been shown to exhibit cell-penetrating capabilities, thus allowing for enhanced cellular uptake [26]. Cell-penetrating peptides (CPPs), such as the TAT protein transduction domain, contain a number of arginine residues [27,28]. Harashima and coworkers demonstrated that liposomes modified with an increasing density of octaarginine (R₈) peptides were taken up *via* macropinocytosis rather than clathrin-mediated endocytosis [29]. Therefore, arginine oligopeptides were also used as the complexation moiety in statistical HPMA brush polymers [25]. Similarly to previous reports comparing arginine motifs with lysine motifs [30-33], HPMA-oligoarginine polymers performed better in transfection efficiency when compared to a lysine analogue (~5-10 mmol lysine or arginine per gram polymer) but also caused increased cytotoxicity. Furthermore, due to challenges in synthesizing oligoarginine peptides, guanidinylation of the lysine residues with *O*-methylisourea was also explored; guanidinylation has been shown to increase transfection efficiencies of various carriers [34-37] and cellular uptake of HPMA constructs [38]. Conversion of the lysine residues in HPMA-oligolysine polymers to homoarginines resulted in higher transfection efficiencies and lower cytotoxicity than bPEI. Therefore, this method could be readily applied to other primary amine-based polymers to increase gene transfer efficiencies.

Degradability using environmentally-responsive elements

Biodegradability is a desirable attribute for the *in vivo* application of gene delivery vectors. Since higher molecular

weights of polycations can lead to increased cytotoxicity [23,24,39,40], linker chemistries have been used to introduce degradability into polymeric vectors. For example, environmentally-responsive linkages such as disulfide and acid-labile bonds can enable the release of cargo in specific intracellular compartments and promote degradability [41]. Likewise, specific amino acid sequences can be enzymatically degraded by various proteases [42-44]. We have explored both of these strategies for introducing a degradable segment into these HPMA-oligolysine polymers. Due to the relatively high levels of glutathione, a reducing agent, in the cytosolic environment compared to the extracellular space [45], the incorporation of disulfide linkages into polymeric carriers has been an attractive approach to increase biodegradability. To introduce reducibility, the six-carbon linker 6-aminohexanoic acid (Ahx) was exchanged with a linker containing a disulfide bond, 3-[(2-aminoethyl)dithio]propionic acid (Aedp) [46]. These reducible polymers were less cytotoxic, but achieved less efficient transfection efficiencies compared to the non-reducible analogue. However, a mixed formulation of reducible and non-reducible polymers achieved an intermediate level of transfection efficiency and reduced cytotoxicity. The high concentration of disulfide bonds within the polymer may lead to chemical instability, which was evidenced by partial improvement in transfection efficiency in the presence of EDTA.

As an alternative approach to enhancing degradability, we explored the use of enzymatically-cleavable peptide linkers, which have been used to introduce site-specific cleavage sites for the release of drugs and peptides [47-49]. A commonly used peptide linker sequence is cathepsin B-labile [12,50]; cathepsin B is a lysosomal cysteine protease that exhibits endo- and exopeptidase activity [51].

We designed a cathepsin B-labile peptide sequence (FKFL), and introduced the linker, flanked by six-carbon spacers (Ahx), between the HPMA backbone and the pendant cationic peptide [52]. The peptides demonstrated site-specific cleavage by cathepsin B within 15 minutes, while the polymers showed complete degradation of the pendant modified oligolysine motifs within 1 hour. In contrast to the reducible polymers in which transfection efficiencies were lower with polymers containing reducible linkers, the cathepsin B-labile polymers showed similar levels of transfection and were less toxic compared to a non-degradable analogue consisting of nondegradable D-amino acids. Therefore, this work demonstrates the possibility of using enzymatically-cleavable linkers to enable site-specific release and degradability for polyplex formulations.

Endosomal escape strategies


Once internalized, polyplexes are exposed to increasingly acidic environments in endosomes and lysosomes, and eventually are degraded by lysosomal proteases. To circumvent lysosomal degradation, various strategies have been investigated to induce endosomal escape, such as the incorporation of peptide moieties that enable proton buffering [53] or interaction with lipid membranes [54]. Virally-derived peptides, such as TAT, Antennapedia (Antp), and HGP, and membrane-disruptive peptides, such as melittin, have been used to increase delivery efficiencies of cargo due to their ability to interact with lipid membranes [3]. We have used both of these approaches to enhance the endosomal escape abilities of our HPMA-oligolysine brush polymers, with varying success [55-57].

As a first approach, we used a similar endosomal escape strategy to bPEI, which is commonly used as a transfection agent due to its ability to induce endosomal escape *via* the buffering of protons at pH ~6-7 [58,59]. Several groups have mimicked this buffering strategy by incorporating histidine residues, which contain a protonable imidazole group at pH 6-7, into various gene carriers [53]. The addition of a second oligohistidine-containing peptide into statistical HPMA-oligolysine polymers demonstrated increased transfection efficiencies [22]. To further optimize the incorporation of oligohistidine peptides to increase transfection, statistical and diblock polymers were synthesized with varying amounts of oligohistidine residues incorporated into the polymer (Figure 3) [55]. Interestingly, the polymer architecture affected the buffering range of the polymer in that diblock polymers buffered in the upper endosomal pH range (pH 5.6-7.4) whereas statistical polymers buffered in the lower endosomal pH range (pH 5.1-6.6). Despite improved buffering capabilities, only the statistical polymer containing 1.4 mmol histidine per gram polymer showed slight improvements in transfection ability over its non-histidylated analogue, possibly due to preferentially trafficking of the polyplexes through the non-acidifying

caveolae-mediated endocytic pathway [60]. Furthermore, endosomal buffering requires a critical concentration threshold to be a viable strategy for endosomal escape, and thus, the use of more potent strategies may be beneficial.

Hydrophobic modification of polycationic polymers is another strategy for promoting endosomal escape. Xu and Szoka proposed that upon endocytosis, lipid-modified polycation/DNA complexes form ion pairs with the negatively-charged amphiphilic endosomal membrane, resulting in membrane destabilization and release of cargo [61]. Furthermore, incorporation of hydrophobic moieties allows for physical encapsulation of the genetic payload, enhanced serum stability, increased cell viability, and targeting ability [62]. Several reviews have been published regarding the advantages of lipid or hydrophobic modification of polycationic gene carriers [63,64]. Previously, Abassi *et al.* reported various lipid-substituted polylysines as vectors for plasmid delivery and expression in skin fibroblasts. They showed that while all modified and unmodified polylysines demonstrated complete complexation with plasmid DNA, polymers with increased lipid substitution were more resistant to unpackaging with heparin treatment. Furthermore, most lipid-modified polymers exhibited increased pEGFP expression compared to native polylysine, with myristic and stearic acid lipid substituents demonstrating less cytotoxicity [65]. Inspired by this work, we prepared a panel of stearic acid-modified copolymers of HPMA and oligolysine. We grafted NHS-activated stearic acid (SA) onto the ϵ -amine of the lysine moiety of the previously optimized *p*(HPMA-*co*-K₁₀) copolymers at DP 190. The lipid substituent was grafted at various lipid to lysine ratios for optimization (Table 1). We then evaluated the polymers for gene transfection. There was no significant increase in gene transfection with these lipid-modified copolymers *in vitro* (Figure 4A); increasing lipid substitution also decreased transfection efficiency (Figure 4B). Interestingly, high lipid substitution showed decreased cytotoxicity. Thus, for these HPMA-oligolysine polymers, lipid substitution is not a viable method for increasing transfection efficiency.

Alternatively, membrane-active peptides have been promising for inducing endosomal escape due to their high disruptive potency [54]. We have investigated the use of melittin, a 26-mer derived from venom of the honey bee *Apis mellifera* [56], and sHGP, a shortened and optimized 15-mer peptide derived from the endodomain of the HIV gp41 region [66]. Melittin undergoes an α -helical conformational change at lipid membranes, allowing the peptide to insert into the membrane and induce pore formation [67,68]. Polymeric carriers conjugated with melittin showed significantly increased transfection *in vitro* and *in vivo* [56,69,70]. Similarly to the HPMA-oligolysine-oligohistidine diblock copolymer, melittin was grafted onto a diblock of *p*[HPMA-*co*-PDSMA]-*b*-[HPMA-*co*-K₁₀],



using PDSMA as the point of conjugation [56]. Incorporation of melittin into these brush polymers displayed hemolytic ability and significantly improved transfection efficiency over the polymer without melittin incorporation, but also increased toxicity. To ameliorate some cytotoxicity, mixed formulations of the base polymer and the melittin-containing polymer were used for transfection and showed

Table 1 Characterization of lipid substitution on *p*[HPMA-co-K₁₀] copolymers

Polymer designation	Lys:Lipid mole ratio	Lipid/HPMA*	% Substituted Lys [#]
<i>p</i> (HPMA-co-K ₁₀ - <i>g</i> -SA) (10:1)	10:1	0.35	14
<i>p</i> (HPMA-co-K ₁₀ - <i>g</i> -SA) (20:1)	20:1	0.21	8.4
<i>p</i> (HPMA-co-K ₁₀ - <i>g</i> -SA) (40:1)	40:1	0.12	4.8

*Based on NMR integration of lipid -CH₂-CO (~ 2.4 ppm) and HPMA -CH(OH)-CH₃ (~ 3.7 ppm).

[#]Based on the theoretical mole ratio (~20% AhxK₁₀ and 80% HPMA): 2.5 mole Lys/1 mole HPMA.

markedly improved toxicity profiles and even further improved transfection efficiencies to greater than that of branched PEI.

The incorporation of sHGP also helped increase the transfection efficiency of HPMA-oligolysine polymers [57]. sHGP was incorporated into HPMA-oligolysine polymers in a diblock architecture, similarly to melittin and the diblock oligohistidine-containing polymer, as well as a statistical architecture. Both polymer architectures demonstrated improved transfection efficiency compared to the base HPMA-oligolysine polymer, but the diblock polymer self-assembled into micelles, thereby sequestering the hydrophobic, membrane-lytic sHGP region. Interestingly, the diblock architecture resulted in less hemolytic activity and improved cytotoxicity profiles. Thus, these results suggest that the exposure of hemolytic regions under certain environmental conditions can lead to more efficient yet less toxic vectors. This strategy has previously been




Figure 4 Transfection of stearic acid (SA)-modified *p*[HPMA-co-K₁₀] polyplexes in HeLa cells. HeLa cells were treated with polyplexes (containing 1 μg plasmid DNA) at charge ratios (N/P) of 3, 5, and 10 for 4 h in serum-free conditions, washed, and replenished with complete media. At 48 h post-transfection, cell lysates were assessed for (A) luciferase reporter gene expression and (B) protein content as an indicator for cytotoxicity. Data are presented as the mean ± S.D., n = 3.

used in the design of synthetic polymers for siRNA delivery, where the exposure of a hydrophobic lytic domain occurred under endosomal pH to facilitate cargo release into the cytosol [71]. To compare these different endosomal escape strategies, cells were transfected with *p*[HPMA-co-K₁₀] containing either oligohistidine, melittin, or sHGP peptides (Figure 5). All polymers that contained endosomal escape modalities performed better than the base polymer containing only oligolysine peptides. The statistical polymer containing oligohistidine peptides and the block polymer containing sHGP performed the best; however, the block sHGP polymer was the least toxic overall.

Design considerations of HPMA-peptide polymers for gene delivery

Salt stability is necessary for the systemic administration of polyplexes since polyplex aggregation can lead to *in vivo* toxicity [72]. The incorporation of HPMA as a hydrophilic segment has been shown to reduce the salt-induced aggregation of multiple polymeric gene delivery systems [73-75]. We have also demonstrated increased salt stability of HPMA-oligolysine polyplexes when compared to lysine peptides or polylysine polyplexes [21-23]. In our optimization studies, salt stability decreased with increasing peptide incorporation [21,22], larger polymer molecular weights, and longer oligolysine peptide lengths [23]. In particular, the latter trend was unexpected

since polymers containing longer oligolysine peptides also had longer HPMA segments in the polymer backbone. The incorporation of a hydrophilic HPMA shell onto *poly*(glycidyl methacrylate-tetraethylenepentamine) (*p*[GMA-TEPA]) also reduced salt-induced aggregation of the polyplexes; in this case, longer hydrophilic segments further enhanced polyplex stability in physiological salt conditions [76]. As seen with polymers containing poly(ethylene glycol) (PEG) to reduce polyplex aggregation under saline conditions [77], polymers containing the HPMA shell also demonstrated decreased *in vitro* transfection efficiencies. These results highlight the tradeoffs of incorporating hydrophilic segments into polymers for enhanced gene delivery *in vivo*.

In order to develop improved materials for nucleic acid delivery, it is important to understand the delivery mechanisms of engineered materials. To further characterize the HPMA-oligolysine polymers, we first determined the uptake efficiency of the optimized oligolysine-containing polymer (*p*[HPMA-co-K₁₀]) (Shi J, Choi JL, Chou B, Johnson RN, Schellinger JG, Pun SH: Effect of polyplex morphology on cellular uptake, intracellular trafficking, and transgene expression. Submitted). Despite much lower polyplex uptake efficiencies of the optimized polymer (*p*[HPMA-co-K₁₀]) vs. bPEI [78], the HPMA-oligolysine polymer achieved similar transfection efficiencies to that of bPEI [23]. Since alternative uptake routes have been




Figure 5 Comparative transfection of *p*[HPMA-co-K₁₀] polymers (“pHK10”) modified with various endosomal escape modalities in HeLa cells. HeLa cells (3×10^4) were treated with polyplexes (containing 1 μ g plasmid DNA) at charge ratios (N/P) of 3, 4, and 5 for 4 h in serum-free conditions, washed, and replenished with complete media. At 48 h post-transfection, cell lysates were assessed for **(A)** luciferase reporter gene expression and **(B)** protein content as an indicator for cytotoxicity. *pHK10* unmodified: *p*[HPMA-co-K₁₀]; *pHK10* + histidine: *p*[HPMA-co-K₁₀-co-K₅H₅] [55]; *pHK10* mix + 5% melittin: a mixture of 95:5% (v/v) *p*[HPMA-co-K₁₀]: *p*[HPMA-co-melittin]-*b*-[HPMA-co-K₁₀] [56]; *pHK10* mix + 15% melittin: a mixture of 85:15% (v/v) *p*[HPMA-co-K₁₀]: *p*[HPMA-co-melittin]-*b*-[HPMA-co-K₁₀]; *pHK10* + melittin: *p*[HPMA-co-melittin]-*b*-[HPMA-co-K₁₀]; *pHK10* + st-sHGP: *p*[HPMA-co-K₁₀-co-sHGP]; *pHK10* + b-sHGP: *p*[HPMA-co-sHGP]-*b*-[HPMA-co-K₁₀]. Data are presented as the mean \pm S.D., n = 3.

implicated in improving polyplex transfection [60], transfection of the HPMA-oligolysine copolymers was also completed with the presence of various endocytic inhibitors [55]. Transfection efficiencies were decreased in the presence of a small-molecule inhibitor for caveolae-mediated endocytosis, a pathway that circumvents the acidification process necessary for endosomal buffering. These results suggest that transfection may be more productive when HPMA-oligolysine polyplexes are routed *via* a non-acidifying endocytic route, similarly to other polycation systems [60,79,80]. Therefore, understanding the uptake pathway of various polymer formulations can aid in the rationale design of improved materials.

Therapeutic applications

Stealth coatings for adenovirus-mediated gene delivery

Adenoviruses, especially adenovirus serotype 5 (Ad5), are effective gene delivery agents since they are able to

transduce both dividing and non-dividing cells, and can be produced in large titers [81,82]. However, Ad5 also induces a host immune response, limiting its use for systemic re-administration, and can only transduce cells expressing Coxsackievirus and Adenovirus Receptor (CAR) and α V integrins on their surface. To reduce the immunogenic response to the Ad5 capsid, as well as enhance the uptake of Ad5 in CAR-negative cell types, synthetic polymers using polyethylene glycol (PEG) and HPMA have been explored as stealth coatings [83]. We have also used HPMA-oligolysine brush polymers, with varying oligolysine peptide lengths, polymer molecular weights, and linker degradability properties, to electrostatically interact with the negatively-charged viral capsid to form stealth coatings [84]. A polymer with a peptide length of ten lysines was optimal for increasing transduction of Ad5 under serum and serum-free conditions; interestingly, a similar polymer was also found to be optimal for nonviral polyplex transfections

[23]. The polymer coatings also enabled transduction of CAR-negative cells, which was mediated by the presence of heparan sulfate proteoglycans (HSPGs) on the cell surface. In particular, sulfated HSPGs have been implicated in enhancing cellular uptake of cationic materials through electrostatic interactions [85]. Furthermore, the stealth coating also significantly protected the virus from neutralizing antibodies, which inhibits efficient *in vivo* viral transduction, without reducing transduction efficiency; these results demonstrated the potential applicability of HPMA-oligolysine brush polymers to enhance Ad5 transduction *in vivo*.

Delivery to the central nervous system (CNS)

The delivery of therapeutic genes to the CNS can be beneficial for the treatment of neurological disorders [86,87]. However, gene delivery to the CNS using nonviral vectors has not been successful due to the low transfection efficiencies achieved in non-dividing cells and low cellular uptake rates in terminally-differentiated neurons [88-90]. One approach to increase efficacy is to conjugate targeting ligands to polymeric vectors to enhance uptake by neuronal subtypes [7,91,92]. We previously demonstrated that conjugation of Tet1, a 12-mer peptide identified by *in vitro* phage display to bind the *Gtb1* ganglioside [93], to polyethylenimine (PEI) enhanced gene delivery to neural progenitor cells (NPCs) [94]. We found that ~0.6 Tet1 per polymer was sufficient to enhance transfection efficiency to NPCs *in vivo*. Recently, we have extended this work by exploring the effect of multivalency on targeting capability by varying ligand density of pendant Tet1 peptides in statistical HPMA-oligolysine copolymers [95]. We showed that there was an optimal ligand density for transfection of neuron-like PC-12 cells (~3 Tet1 per polymer), mainly due to increased toxicities seen with higher Tet1 ligand incorporation. Interestingly, high concentrations (> 100 μ M) of the Tet1 peptide alone did not cause significant cytotoxicity, suggesting that the incorporation of hydrophobic peptides such as Tet1 can increase the toxicity of cationic polymers [63].

Another approach for increasing transfection efficiency to neurons is to enhance endosomal escape of endocytosed polyplexes [96]. We have also demonstrated that melittin-containing HPMA polymer carriers enhanced effective bulk luciferase transfection to the brain over polymers without melittin after intraventricular injection [56].

Conclusions and future directions

In summary, we have demonstrated the synthesis of cationic polymers consisting of a hydrophilic HPMA backbone with multiple pendant peptides for DNA condensation, degradability, and endosomal escape. These HPMA-peptide brush polymers have also been used to improve adenovirus transduction and targeted delivery to the central nervous system. The relatively simple polymerization strategy used to synthesize these polymers has allowed the investigation

of peptide multivalency, polymer architecture, and the use of various bioactive peptides for gene delivery applications. Currently, we are applying our findings from these described studies to improve other gene delivery systems for *in vivo* delivery. More broadly, our enhanced understanding of the delivery mechanisms of these HPMA-peptide materials is applicable to other gene delivery systems. Furthermore, these versatile materials have shown potential for the general delivery of biologics, such as therapeutic peptides and proteins.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

JS compared the transfection efficiencies of polymers modified with endosomal release moieties, JGS synthesized and tested lipid-modified carriers, and JS and SHP prepared the manuscript. All authors read and approved the final manuscripts.

Acknowledgements

This work is supported by NIH/NINDS 1R01NS064404, DMR 1206426, and the Center for the Intracellular Delivery of Biologics through the Washington Life Sciences Discovery Fund Grant No. 2496490. J.S. is supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE-0718124. We thank Dr. Russell Johnson and David Chu for helpful discussion.

Received: 23 August 2013 Accepted: 17 October 2013

Published: 24 October 2013

References

1. Pack DW, Hoffman AS, Pun S, Stayton PS: Design and development of polymers for gene delivery. *Nat Rev Drug Discov* 2005, **4**:581-593.
2. Bergen JM, Pun SH: Peptide-enhanced nucleic acid delivery. *MRS bulletin* 2005, **30**:663-667.
3. Gopal V: Bioinspired peptides as versatile nucleic acid delivery platforms. *J Control Release* 2013, **167**:323-332.
4. Martin ME, Rice KG: Peptide-guided gene delivery. *AAPS J* 2007, **9**:E18-29.
5. Levine RM, Scott CM, Kokkoli E: Peptide functionalized nanoparticles for nonviral gene delivery. *Soft Matter* 2013, **9**:985-1004.
6. Kogure K, Akita H, Yamada Y, Harashima H: Multifunctional envelope-type nano device (MEND) as a non-viral gene delivery system. *Adv Drug Deliv Rev* 2008, **60**:559-571.
7. Kwon EJ, Bergen JM, Park IK, Pun SH: Peptide-modified vectors for nucleic acid delivery to neurons. *J Control Release* 2008, **132**:230-235.
8. Nishikawa M, Yamauchi M, Morimoto K, Ishida E, Takakura Y, Hashida M: Hepatocyte-targeted *in vivo* gene expression by intravenous injection of plasmid DNA complexed with synthetic multi-functional gene delivery system. *Gene Ther* 2000, **7**:548-555.
9. Chu DSH, Schellinger JG, Shi J, Convertine AJ, Stayton PS, Pun SH: Application of living free radical polymerization for nucleic acid delivery. *Acc Chem Res* 2012, **45**:1089-1099.
10. Ahmed M, Narain R: Progress of RAFT Based Polymers in Gene Delivery. *Prog Polym Sci* 2013, **38**:767-790.
11. Xu F, Yang W: Polymer vectors via controlled/living radical polymerization for gene delivery. *Prog Polym Sci* 2011, **36**:1099-1131.
12. Kopecek J, Kopecková P, Minko T, Lu Z: HPMA copolymer-anticancer drug conjugates: design, activity, and mechanism of action. *Eur J Pharm Biopharm* 2000, **50**:61-81.
13. Bulmus V: RAFT polymerization mediated bioconjugation strategies. *Polym Chem* 2011, **2**:1463-1472.
14. Gregory A, Stenzel MH: Progress in Polymer Science. *Prog Polym Sci* 2012, **37**:38-105.
15. Apostolovic B, Deacon SPE, Duncan R, Klok H-A: Hybrid polymer therapeutics incorporating bioresponsive, coiled coil peptide linkers. *Biomacromolecules* 2010, **11**:1187-1195.

16. Wu GY, Wu CH: Receptor-mediated in vitro gene transformation by a soluble DNA carrier system. *J Biol Chem* 1987, **262**:4429–4432.
17. Toncheva V, Wolfert MA, Dash PR, OUPICKY D, Ulbrich K, Seymour LW, Schacht EH: Novel vectors for gene delivery formed by self-assembly of DNA with poly(L-lysine) grafted with hydrophilic polymers. *Biochim Biophys Acta* 1998, **1380**:354–368.
18. Mintzer MA, Simanek EE: Nonviral vectors for gene delivery. *Chem Rev* 2009, **109**:259–302.
19. O'Brien-Simpson NM, Ede NJ, Brown LE, Swan J, Jackson DC: Polymerization of unprotected synthetic peptides: A view toward synthetic peptide vaccines. *J Am Chem Soc* 1997, **119**:1183–1188.
20. Kopeček J, Kopečková P: HPMA copolymers: origins, early developments, present, and future. *Adv Drug Deliv Rev* 2010, **62**:122–149.
21. Burke RS, Pun SH: Synthesis and characterization of biodegradable HPMA-oligolysine copolymers for improved gene delivery. *Bioconjug Chem* 2010, **21**:140–150.
22. Johnson RN, Burke RS, Convertine AJ, Hoffman AS, Stayton PS, Pun SH: Synthesis of Statistical Copolymers Containing Multiple Functional Peptides for Nucleic Acid Delivery. *Biomacromolecules* 2010, **11**:3007–3013.
23. Johnson RN, Chu DSH, Shi J, Schellinger JG, Carlson PM, Pun SH: HPMA-oligolysine copolymers for gene delivery: optimization of peptide length and polymer molecular weight. *J Control Release* 2011, **155**:303–311.
24. Hwang SJ, Bellocq NC, Davis ME: Effects of structure of beta-cyclodextrin-containing polymers on gene delivery. *Bioconjug Chem* 2001, **12**:280–290.
25. Carlson PM, Schellinger JG, Pahang JA, Johnson RN, Pun SH: Comparative study of guanidine-based and lysine-based brush copolymers for plasmid delivery. *Biomater Sci* 2013, **1**:736–744.
26. El-Sayed A, Futaki S, Harashima H: Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. *AAPS J* 2009, **11**:13–22.
27. Brooks H, Lebleu B, Vives E: Tat peptide-mediated cellular delivery: back to basics. *Adv Drug Deliv Rev* 2005, **57**:559–577.
28. Torchilin VP: Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. *Adv Drug Deliv Rev* 2008, **60**:548–558.
29. Khalil IA, Kogure K, Futaki S, Harashima H: High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. *J Biol Chem* 2006, **281**:3544–3551.
30. Okuda T, Sugiyama A, Niidome T, Aoyagi H: Characters of dendritic poly(L-lysine) analogues with the terminal lysines replaced with arginines and histidines as gene carriers in vitro. *Biomaterials* 2004, **25**:537–544.
31. El-Sayed A, Khalil IA, Kogure K, Futaki S, Harashima H: Octaarginine- and octalysine-modified nanoparticles have different modes of endosomal escape. *J Biol Chem* 2008, **283**:23450–23461.
32. Naik RJ, Chandra P, Mann A, Ganguli M: Exogenous and cell surface glycosaminoglycans alter DNA delivery efficiency of arginine and lysine homopeptides in distinctly different ways. *J Biol Chem* 2011, **286**:18982–18993.
33. Årmand HL, Rydberg HA, Fornander LH, Lincoln P, Nordén B, Esbjörner EK: Cell surface binding and uptake of arginine- and lysine-rich penetrating peptides in absence and presence of proteoglycans. *Biochim Biophys Acta* 2012, **1818**:2669–2678.
34. Bromberg L, Radyuk S, Hatton TA, Concheiro A, Rodriguez-Valencia C, Silva M, Alvarez-Lorenzo C: Guanidinylated polyethyleneimine-polyoxypropylene-polyoxyethylene conjugates as gene transfection agents. *Bioconjug Chem* 2009, **20**:1044–1053.
35. Tziveleka L-A, Psarra A-MG, Tsiourvas D, Paleos CM: Synthesis and characterization of guanidinylated poly(propylene imine) dendrimers as gene transfection agents. *J Control Release* 2007, **117**:137–146.
36. Zhai X, Sun P, Luo Y, Ma C, Xu J, Liu W: Guanidinylation: A Simple Way to Fabricate Cell Penetrating Peptide Analogue-Modified Chitosan Vector for Enhanced Gene Delivery. *J Appl Polym Sci* 2011, **121**:3569–3578.
37. Mattheis C, Wang H, Meister C, Agarwal S: Effect of guanidinylation on the properties of poly(2-aminoethylmethacrylate)-based antibacterial materials. *Macromol Biosci* 2013, **13**:242–255.
38. Treat NJ, Smith D, Teng C, Flores JD, Abel BA, York AW, Huang F, McCormick CL: Guanidine-Containing Methacrylamide (Co)polymers via aRAFT: Toward a Cell Penetrating Peptide Mimic(). *ACS Macro Lett* 2012, **1**:100–104.
39. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T: In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. *Biomaterials* 2003, **24**:1121–1131.
40. De Wolf HK, De Raad M, Snel C, Van Steenbergen MJ, Fens MHAM, Storm G, Hennink WE: Biodegradable poly(2-dimethylamino ethylamino) phosphazene for in vivo gene delivery to tumor cells. Effect of polymer molecular weight. *Pharm Res* 2007, **24**:1572–1580.
41. Ganta S, Devalapally H, Shahiwala A, Amiji M: A review of stimuli-responsive nanocarriers for drug and gene delivery. *J Control Release* 2008, **126**:187–204.
42. Dubowchik GM, Firestone RA, Padilla L, Willner D, Hofstead SJ, Mosure K, Knipe JO, Lasch SJ, Trail PA: Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity. *Bioconjug Chem* 2002, **13**:855–869.
43. Lévesque SG, Shoichet MS: Synthesis of enzyme-degradable, peptide-cross-linked dextran hydrogels. *Bioconjug Chem* 2007, **18**:874–885.
44. Grosse SM, Tagalakis AD, Mustapa MFM, Elbs M, Meng Q-H, Mohammadi A, Tabor AB, Hailes HC, Hart SL: Tumor-specific gene transfer with receptor-mediated nanocomplexes modified by polyethylene glycol shielding and endosomally cleavable lipid and peptide linkers. *FASEB J* 2010, **24**:2301–2313.
45. Meister A, Anderson m: Glutathione. *Annu Rev Biochem* 1983, **52**:711–760.
46. Shi J, Johnson RN, Schellinger JG, Carlson PM, Pun SH: Reducible HPMA-co-oligolysine copolymers for nucleic acid delivery. *Int J Pharm* 2012, **427**:113–122.
47. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY: Tumor imaging by means of proteolytic activation of cell-penetrating peptides. *Proc Natl Acad Sci U S A* 2004, **101**:17867–17872.
48. Hatakeyama H, AKITA H, Kogure K, Oishi M, Nagasaki Y, Kihira Y, Ueno M, Kobayashi H, Kikuchi H, HARASHIMA H: Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. *Gene Ther* 2007, **14**:68–77.
49. Ulijn RV: Enzyme-responsive materials: a new class of smart biomaterials. *J Mater Chem* 2006, **16**:2217–2225.
50. Sutherland MSK, Sanderson RJ, Gordon KA, Andreyka J, Cerveny CG, Yu C, Lewis TS, Meyer DL, Zabinski RF, Doronina SO, Senter PD, Law C-L, Wahl AF: Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-aurostatin conjugates. *J Biol Chem* 2006, **281**:10540–10547.
51. Turk V, Turk B, Turk D: Lysosomal cysteine proteases: facts and opportunities. *EMBO J* 2001, **20**:4629–4633.
52. Chu DSH, Johnson RN, Pun SH: Cathepsin B-sensitive polymers for compartment-specific degradation and nucleic acid release. *J Control Release* 2012, **157**:445–454.
53. Midoux P, Pichon C, Yaouanc J-J, Jaffrés P-A: Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. *Br J Pharmacol* 2009, **157**:166–178.
54. Wagner E: Application of membrane-active peptides for nonviral gene delivery. *Adv Drug Deliv Rev* 1999, **38**:279–289.
55. Shi J, Schellinger JG, Johnson RN, Choi JL, Chou B, Anghel EL, Pun SH: Influence of Histidine Incorporation on Buffer Capacity and Gene Transfection Efficiency of HPMA-co-oligolysine Brush Polymers. *Biomacromolecules* 2013, **14**:1961–1970.
56. Schellinger JG, Pahang JA, Johnson RN, Chu DSH, Sellers DL, Maris DO, Convertine AJ, Stayton PS, Horner PJ, Pun SH: Melittin-grafted HPMA-oligolysine based copolymers for gene delivery. *Biomaterials* 2013, **34**:2318–2326.
57. Schellinger JG, Pahang JA, Shi J, Pun SH: Block Copolymers Containing a Hydrophobic Domain of Membrane-Lytic Peptides Form Micellar Structures and Are Effective Gene Delivery Agents. *ACS Macro Lett* 2013, **2**:725–730.
58. Kichler A, Leborgne C, Coeytaux E, Danos O: Polyethyleneimine-mediated gene delivery: a mechanistic study. *J Gene Med* 2001, **3**:135–144.
59. Akinc A, Thomas M, Klibanov AM, Langer R: Exploring polyethyleneimine-mediated DNA transfection and the proton sponge hypothesis. *J Gene Med* 2005, **7**:657–663.
60. Reilly MJ, Larsen JD, Sullivan MO: Polyplexes traffic through caveolae to the Golgi and endoplasmic reticulum en route to the nucleus. *Mol Pharm* 2012, **9**:1280–1290.
61. Xu Y, Szoka FC: Mechanism of DNA release from cationic liposome/DNA complexes used in cell transfection. *Biochemistry* 1996, **35**:5616–5623.
62. Liu Z, Zhang Z, Zhou C, Jiao Y: Hydrophobic modifications of cationic polymers for gene delivery. *Prog Polym Sci* 2010, **35**:1144–1162.

63. Incani V, Lavasanifar A, Uludağ H: **Lipid and hydrophobic modification of cationic carriers on route to superior gene vectors.** *Soft Matter* 2010, **6**:2124–2138.
64. Zhu L, Mahato RI: **Lipid and polymeric carrier-mediated nucleic acid delivery.** *Expert Opin Drug Deliv* 2010, **7**:1209–1226.
65. Abbasi M, Uludağ H, Incani V, Hsu CYM, Jeffery A: **Further investigation of lipid-substituted poly(L-Lysine) polymers for transfection of human skin fibroblasts.** *Biomacromolecules* 2008, **9**:1618–1630.
66. Kwon EJ, Liong S, Pun SH: **A truncated HGP peptide sequence that retains endosomolytic activity and improves gene delivery efficiencies.** *Mol Pharm* 2010, **7**:1260–1265.
67. Juvvadi P, Vunnam S, Merrifield RB: **Synthetic melittin, its enantio, retro, and retroenantio isomers, and selected chimeric analogs: their antibacterial, hemolytic, and lipid bilayer action.** *J Am Chem Soc* 1996, **118**:8989–8997.
68. Raghuraman H, Chattopadhyay A: **Melittin: a membrane-active peptide with diverse functions.** *Biosci Rep* 2007, **27**:189–223.
69. Ogris M, Carlisle RC, Bettinger T, Seymour LW: **Melittin enables efficient vesicular escape and enhanced nuclear access of nonviral gene delivery vectors.** *J Biol Chem* 2001, **276**:47550–47555.
70. Baumhover NJ, Anderson K, Fernandez CA, Rice KG: **Synthesis and in vitro testing of new potent polyacridine-melittin gene delivery peptides.** *Bioconjug Chem* 2010, **21**:74–83.
71. Convertine AJ, Benoit DSW, Duvall CL, Hoffman AS, Stayton PS: **Development of a novel endosomolytic diblock copolymer for siRNA delivery.** *J Control Release* 2009, **133**:221–229.
72. Ogris M, Brunner S, Schüller S, Kircheis R, Wagner E: **PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery.** *Gene Ther* 1999, **6**:595–605.
73. OUPICKY D, Howard KA, Konák C, Dash PR, Ulbrich K, Seymour LW: **Steric stabilization of poly-L-Lysine/DNA complexes by the covalent attachment of semitelechelic poly[N-(2-hydroxypropyl)methacrylamide].** *Bioconjug Chem* 2000, **11**:492–501.
74. Oupický D, Ogris M, Howard KA, Dash PR, Ulbrich K, Seymour LW: **Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation.** *Mol Ther* 2002, **5**:463–472.
75. Šubr V, Koňák C, Laga R, Ulbrich K: **Coating of DNA/poly(L-lysine) complexes by covalent attachment of poly[N-(2-hydroxypropyl)methacrylamide].** *Biomacromolecules* 2006, **7**:122–130.
76. Wei H, Pahang JA, Pun SH: **Optimization of brush-like cationic copolymers for nonviral gene delivery.** *Biomacromolecules* 2013, **14**:275–284.
77. Hatakeyama H, Akita H, Harashima H: **A multifunctional envelope type nano device (MEND) for gene delivery to tumours based on the EPR effect: a strategy for overcoming the PEG dilemma.** *Adv Drug Deliv Rev* 2011, **63**:152–160.
78. Shi J, Chou B, Choi JL, Ta AL, Pun SH: **Investigation of Polyethylenimine/DNA Polyplex Transfection to Cultured Cells Using Radiolabeling and Subcellular Fractionation Methods.** *Mol Pharm* 2013, **10**:2145–2156.
79. Fichter KM, Ingle NP, McLendon PM, Reineke TM: **Polymeric nucleic acid vehicles exploit active interorganelle trafficking mechanisms.** *ACS Nano* 2013, **7**:347–364.
80. McLendon PM, Fichter KM, Reineke TM: **Poly(glycoamidoamine) vehicles promote pDNA uptake through multiple routes and efficient gene expression via caveolae-mediated endocytosis.** *Mol Pharm* 2010, **7**:738–750.
81. Chailertvanitkul VA, Pouton CW: **Adenovirus: a blueprint for non-viral gene delivery.** *Curr Opin Biotechnol* 2010, **21**:627–632.
82. Jang J-H, Schaffer DV, Shea LD: **Engineering biomaterial systems to enhance viral vector gene delivery.** *Mol Ther* 2011, **19**:1407–1415.
83. Kreppel F, Kochanek S: **Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide.** *Mol Ther* 2008, **16**:16–29.
84. Wang C-HK, Chan LW, Johnson RN, Chu DSH, Shi J, Schellinger JG, Lieber A, Pun SH: **The transduction of Cocksackie and Adenovirus Receptor-negative cells and protection against neutralizing antibodies by HPMA-co-oligolysine copolymer-coated adenovirus.** *Biomaterials* 2011, **32**:9536–9545.
85. Ruponen M, Rönkkö S, Honkakoski P, Pelkonen J, Tammi M, Urtti A: **Extracellular glycosaminoglycans modify cellular trafficking of lipoplexes and polyplexes.** *J Biol Chem* 2001, **276**:33875–33880.
86. Davidson BL, Breakefield XO: **Viral vectors for gene delivery to the nervous system.** *Nat Rev Neurosci* 2003, **4**:353–364.
87. Rogers M-L, Rush RA: **Non-viral gene therapy for neurological diseases, with an emphasis on targeted gene delivery.** *J Control Release* 2012, **157**:183–189.
88. Pérez-Martínez FC, Guerra J, Posadas I, Ceña V: **Barriers to non-viral vector-mediated gene delivery in the nervous system.** *Pharm Res* 2011, **28**:1843–1858.
89. Suk JS, Suh J, Choy K, Lai SK, Fu J, Hanes J: **Gene delivery to differentiated neurotypic cells with RGD and HIV Tat peptide functionalized polymeric nanoparticles.** *Biomaterials* 2006, **27**:5143–5150.
90. Bergen JM, Pun SH: **Analysis of the intracellular barriers encountered by nonviral gene carriers in a model of spatially controlled delivery to neurons.** *J Gene Med* 2008, **10**:187–197.
91. Zeng J, Too H-P, Ma Y, Luo ESE, Wang S: **A synthetic peptide containing loop 4 of nerve growth factor for targeted gene delivery.** *J Gene Med* 2004, **6**:1247–1256.
92. Oliveira H, Fernandez R, Pires LR, Martins MCL, Simões S, Barbosa MA, Pêgo AP: **Targeted gene delivery into peripheral sensorial neurons mediated by self-assembled vectors composed of poly(ethylene imine) and tetanus toxin fragment c.** *J Control Release* 2010, **143**:350–358.
93. Liu JK, Teng Q, Garrity-Moses M, Federici T, Tanase D, Imperiale MJ, Boulis NM: **A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting.** *Neurobiol Dis* 2005, **19**:407–418.
94. Kwon EJ, Lasiene J, Jacobson BE, Park I-K, Horner PJ, Pun SH: **Targeted nonviral delivery vehicles to neural progenitor cells in the mouse subventricular zone.** *Biomaterials* 2010, **31**:2417–2424.
95. Chu DSH, Schellinger JG, Bocek MJ, Johnson RN, Pun SH: **Optimization of Tet1 Ligand Density in HPMA-Co-Oligolysine Copolymers for Targeted Neuronal Gene Delivery.** *Biomaterials* 2013, **34**:9632–9637.
96. Suk JS, Suh J, Lai SK, Hanes J: **Quantifying the intracellular transport of viral and nonviral gene vectors in primary neurons.** *Exp Biol Med* 2007, **232**:461–469.

doi:10.1186/1754-1611-7-25

Cite this article as: Shi et al.: Engineering biodegradable and multifunctional peptide-based polymers for gene delivery. *Journal of Biological Engineering* 2013 **7**:25.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

